AstraZeneca Buys Lung Cancer Drug Zegfrovy in $1.5B Dizal Deal
AstraZeneca Acquires Zegfrovy for $1.5 Billion to Strengthen Oncology Portfolio AstraZeneca has secured exclusive global rights to Dizal Pharmaceutical’s oral EGFR lung cancer drug Zegfrovy (sunvozertinib) in a transaction valued … Read More